Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
US-2015299677-A1 · Oct 22, 2015 · US
Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US9452197B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9452197-B2 |
| Application number | US-201314142094-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 27, 2013 |
| Priority date | Nov 2, 2006 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
First claim
Opening claim text (preview).
We claim: 1. A method of inhibiting angiogenesis in a mammal, the method comprising, administering to the mammal an effective amount of an antibody or antigen-binding antibody fragment that binds to BMP10. 2. The method of claim 1 , wherein the method further comprises administering a second agent that inhibits angiogenesis. 3. The method of claim 1 , wherein the angiogenesis to be inhibited is angiogenesis occurring, in a tumor. 4. The method of claim 1 wherein the mammal has angiogenesis related rheumatoid arthritis and wherein the antibody or antigen-binding antibody fragment inhibits the binding of BMP10 to ALK1. 5. The method of claim 1 wherein the mammal has an angiogenesis related disease of the eye and wherein the antibody or antigen-binding antibody fragment inhibits the binding of BMP10 to ALK1.S. 6. The method of claim 1 , wherein the antibody or antigen-binding antibody fragment inhibits the binding of BMP10 to ALK1. 7. A method of inhibiting angiogenesis in a tumor in a mammal, the method comprising, administering to a mammal that has a tumor an effective amount of an antibody or antigen-binding antibody fragment that binds BMP10 and inhibits the binding of BMP10 to ALK1.
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K38/1709Primary
from mammals · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9452197B2 cover?
- In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligand…
- Who is the assignee on this patent?
- Acceleron Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).